🧾 What This Document Is

This is a DEF 14A, or "Proxy Statement." Think of it as an invitation and a handbook for Neogenomics' upcoming annual shareholder meeting. It's where the company formally asks shareholders to vote on key issues, like electing the board of directors and approving executive pay. The meeting is virtual on May 21, 2026, and this document explains what you're voting on and why.

🏢 What The Company Does

👉 In simple terms... Neogenomics is a cancer testing lab. They analyze tissue and blood samples to help doctors diagnose cancer, understand its specific genetic makeup, and choose the best treatments. They operate in the specialized and fast-growing field of oncology diagnostics.

🗳️ The 4 Things Shareholders Are Voting On

The meeting has four main proposals. The Board recommends a "FOR" vote on all of them.

Proposal 1: Elect the Board of Directors. Shareholders will vote on 9 nominees, including the current CEO, Tony Zook. The Board emphasizes that 8 of the 9 are independent outsiders.
Proposal 2: Approve Executive Pay (Say-on-Pay). This is a non-binding vote on whether shareholders approve the compensation paid to top executives. Last year, this passed with 82% support.
Proposal 3: Approve an Updated Equity Plan. This asks to amend the 2023 Equity Incentive Plan, likely to add more shares available to grant as stock awards to employees and directors.
Proposal 4: Ratify the Auditor. Shareholders are asked to approve Deloitte & Touche LLP as the company's independent accounting firm for 2026.

👥 Meet The Board & Leadership

The Board is led by Non-Executive Chair Lynn Tetrault, who has deep pharma industry experience. The CEO is Tony Zook, who took the top job in April 2025. The board has several committees, each focused on different areas like Audit, Compensation, Innovation, and Governance. They highlight that all committees are made up entirely of independent directors.

💼 Executive Compensation: What Changed & Why

This section is crucial as it's a direct response to shareholder feedback from last year.

Base Salaries: The new CEO, Tony Zook, has a base salary of $850,000. Other top executives received raises between 3.5% and 14.5%.
The Big Shift for 2025: To better link pay with performance (a major shareholder request), 50% of executives' long-term stock awards are now "premium-priced stock options." These options only become valuable if the stock price rises by at least 10%, aligning executive gains directly with shareholder returns.
Philosophy: The company says its pay-for-performance philosophy is designed to attract and retain talent while driving long-term strategy focused on growth, innovation, and operational excellence.

⚖️ Corporate Governance Highlights

Neogenomics is stressing its strong governance practices to reassure shareholders.

👍 Strengths & Best Practices:

Independent Board: 8 of 9 director nominees are independent.
Separate Chair & CEO: The roles are split to increase independence.
Active Engagement: The company met with stockholders representing ~60% of shares in 2025 to hear their concerns.
No Hedging/Pledging: Insiders are prohibited from hedging or pledging company stock.
Ownership Guidelines: Directors and executives must hold significant company stock, aligning them with shareholders.

⚠️ Risks to Watch:

CEO Transition: The company just completed a CEO change in April 2025. New leadership always carries execution risk.
Industry Competition: The oncology diagnostics field is competitive and technologically fast-moving.
Financial Performance: Like many companies, it must navigate economic pressures while investing in growth.

🧠 The Analogy

Think of Neogenomics like a specialized GPS for oncologists. Instead of just saying "turn left," their tests tell the doctor exactly what kind of "road" (cancer mutation) the patient is on and which "routes" (treatments) are most likely to succeed. The Proxy Statement is the owner's manual for the company itself, letting the shareholders (the owners) vote on who gets to steer the board (the directors) and how the captain (the CEO) is paid for the journey.

🧩 Final Takeaway

This proxy statement shows a company actively responding to shareholder concerns by shifting executive pay more toward performance-based options and emphasizing board independence. The key for investors is to assess whether the new leadership and governance strategies will successfully drive growth and value in the competitive cancer diagnostics market. Your vote matters on all four proposals.

NEOGENOMICS INC — DEF 14A Filing